Skip to main content

Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

Agency: Food and Drug Administration

Assistance Listings
  • 93.103 -- Food and Drug Administration Research

Forecasted opportunityLast Updated: May 13, 2026

Important dates

  • Forecasted post date: Not specified
  • Forecasted application due date: Not specified
  • Forecasted award date: Not specified
  • Forecasted project start date: Not specified
  • Fiscal Year: 2024

Award details

  • Expected project funding: Not specified
  • Expected awards: 2

Award min.

$250,000

Award max.

$500,000

  • Funding opportunity number:FOR-FD-24-005
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Cooperative agreement
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Consumer protection
    • Agriculture
    • Food and nutrition
  • Category Explanation:Not specified

History

  • Forecast posted date: November 24, 2023
  • Archive date: Not specified
  • Version: 2

View version history on Grants.gov

Summary

The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to develop and validate the in vitro mechanistic methodology to provide an improved understanding of impact of food and acid reducing agents on the absorption for test and reference listed drug (RLD) drug products, taking into consideration their potentially different formulations and manufacturing. The bio predictive in vitro mechanistic methodology is intended to correlate the in vitro observations to in vivo outcomes, help define types of in vivo bioequivalence (BE) studies needed for ASD drug products, and inform regulatory decision-making related to mitigating the risk of potential failure modes for therapeutic equivalence for high-risk generic oral drug products. 

Eligibility

Nonprofit

  • Other Native American tribal organizations
  • Nonprofits non-higher education without 501(c)(3)
  • Nonprofits non-higher education with 501(c)(3)

Education

  • Public and state institutions of higher education
  • Private institutions of higher education
  • Independent school districts

Business

  • For-profit organizations other than small businesses
  • Small businesses

Government

  • Federally recognized Native American tribal governments
  • State governments
  • Special district governments
  • County governments
  • City or township governments
  • Public and Indian housing authorities

Miscellaneous

  • Unrestricted
  • Other

Additional information on eligibility

Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Documents

No documents are currently available.

Agency contact information

Email: terrin.brown@fda.hhs.gov

terrin.brown@fda.hhs.gov

Terrin Brown Grantor (240) 402-7610

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov